Solvay Pharmaceuticals currently has a rich R&D portfolio with some 30 molecules to feed the future growth of our company. The picture below provides an overview of our current R&D pipeline. 

Some interesting examples highlighted

Schizofrenia
Solvay Pharmaceuticals signed extensive agreements with Lundbeck and Wyeth Pharmaceuticals to co-develop and co-commercialize several central nervous system (CNS) compounds. One of the compounds in a final stage of development is bifeprunox for the possible treatment of schizophrenia. The New Drug Application (NDA) for bifeprunox submitted to the U.S. Food and Drug Administration (FDA) in October 2006 has been officially filed by the FDA. This means that the formal processing and review period both begin.
 
Bifeprunox and the other three SLV compounds are the product of Solvay Pharmaceuticals’ research and developments efforts

Obesity
Another compound (SLV 319) in development together with Bristol Myers Squibb is for the treatment of obesity. Obesity is not a simple condition of eating too much. It is now recognized that obesity is a serious, chronic disease. Obesity is defined as an excessively high amount of body fat in relation to lean body mass. The cause of obesity differs from one person to another. Genetic, environmental, psychological, and other factors may all play part.
 
Obesity is considered to be a real health hazard. According to the World Health Organization, in 1995, there were an estimated 200 million obese adults worldwide and another 18 million under-five children classified as overweight. As of 2000, the number of obese adults has increased to over 300 million.
Several serious medical conditions have been linked to obesity, including diabetes, heart disease, high blood pressure and stroke. Obesity is also linked to higher rates of certain types of cancer.